Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CB-0406 in Healthy Volunteers
NCT04467684Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CB-0406 in Inflammatory Disorders (6 arms), sponsored by Gilead Sciences. Primary endpoint: Pharmacokinetic Parameters. Started Jul 2020; status: completed.
02
Drugs
CB-0406
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NCT04467684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04467684.